SUBSCRIBE
SUBSCRIBE

Corcept Therapeutics

NEWS
Biotech Beach
The Day In Review: Immunicon Corporation Rises On AstraZeneca PLC Deal
August 7, 2006
 · 
1 min read
Biotech 2005: New Drugs Hold The Key
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
June 5, 2025
 · 
6 min read
Press Releases
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
June 2, 2025
 · 
7 min read
Press Releases
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
May 5, 2025
 · 
11 min read
Press Releases
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
April 28, 2025
 · 
1 min read
Press Releases
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
April 21, 2025
 · 
4 min read
Press Releases
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
April 7, 2025
 · 
3 min read
Press Releases
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
March 10, 2025
 · 
3 min read
Press Releases
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
March 3, 2025
 · 
3 min read
Press Releases
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
February 26, 2025
 · 
10 min read
Press Releases
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
February 12, 2025
 · 
1 min read
Load More